AI In Post - Surveillance Market - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI in post -Market surveillance market size was valued at USD 0.66 billion in 2025 and is estimated to grow from USD 0.76 billion in 2026 to reach USD 1.5 billion by 2031, at a CAGR of 15.45% during the forecast period (2026-2031). This report is Segmented by Application (Adverse Event Reporting & Case Processing, and More), End User (Pharmaceutical Companies, Biotechnology Companies, and More), Deployment Mode (Cloud, On-Premises, Hybrid), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global AI In Post -Market Surveillance Market Trends and Insights

Regulatory Mandates Intensify PMS/PV Digitization

Health authorities are strengthening surveillance regulations as accelerated approvals shift evidence generation downstream. The FDA’s October 2026 ICH E2B(R3) deadline eliminates free-text narratives, a change that previously accounted for 60% of case-processing time at several firms. EMA’s electronic Periodic Safety Update Report requirement and the UK regulator’s 2024 medical-device guidance further highlight the non-compliance of manual workflows. China’s revised Pharmacovigilance Inspection Guidelines have assigned Marketing Authorization Holder responsibilities, driving a 40% increase in cloud safety-platform purchases in 2025. Collectively, these mandates establish a digital baseline that only AI-enabled systems can meet within statutory timelines.

Regulatory Acceptance of RWE Elevates Analytics Demand

Real-world evidence now directly influences label updates and benefit-risk assessments, encouraging companies to integrate AI into their analytics frameworks. The FDA Sentinel System utilized natural-language processing in 2025 to extract adverse events from 700 million patient records, reducing false-negative signal rates by 30%. EMA’s 2024 guidance permits sponsors to apply machine-learning models for confounding adjustments, provided they disclose validation methods. Sanofi’s Project ARTEMIS, which processes 700,000 cases annually, achieved 15% cost savings in 2025 and aims for 50% by 2027 by combining AI-driven case intake with real-world evidence analytics.

AI Models Face GxP Validation and Explainability Challenges

The ISPE GAMP AI guide, a comprehensive 290-page document, expands traditional computer-system validation to include model training, drift monitoring, and interpretability. This development increases entry barriers for smaller biotech firms. The FDA's "Good AI Practice" framework, set to be implemented in January 2026, requires sensitivity analyses and external validation for high-stakes predictions, potentially delaying deployment timelines by several months. Additionally, CIOMS guidance mandates human review of every AI-generated safety signal before submission, limiting automation to approximately 70% of the workflow for end-to-end straight-through processing.

Other drivers and restraints analyzed in the detailed report include:

• Migration to ICH E2B(R3) Standardizes Structured Safety Data
• Cloud-First PV/PMS Architectures Reduce TCO and Speed Rollouts
• Interoperability Challenges and E2B(R3) Readiness Delays

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Adverse Event Reporting & Case Processing accounted for 34.18% of the AI-driven post-market surveillance revenue, representing the largest market share. This segment grew as companies efficiently converted unstructured data such as emails, call-center transcripts, and physician letters into structured E2B(R3) messages, meeting regulatory requirements. Meanwhile, Signal Detection & Risk Management is projected to grow at a strong 17.88% CAGR through 2031, reflecting a shift toward proactive risk management as routine case intake processes become automated. The market for signal analytics is expanding as organizations integrate natural-language models to analyze spontaneous reports, EHR extracts, and literature for early safety signals. For example, advancements in duplicate-case identification have significantly reduced per-case costs, enhancing operational efficiency.

Complete Report Scope:

• By Application
  • Adverse Event Reporting & Case Processing
  • Signal Detection & Risk Management
  • Literature & Social Media Monitoring
  • Regulatory Reporting & Case Submission (ICSR E2B(R3))
  • Real-World Evidence & Safety Analytics
  • Others
• By End User
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Manufacturers
  • CROs/BPOs & PV Service Providers
  • Regulatory Authorities & Notified Bodies
• By Deployment Mode
  • Cloud (SaaS)
  • On-Premises
  • Hybrid
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America accounted for 43.18% of the revenue, driven by the FDA's ICH E2B(R3) deadline in October 2026 and the expansion of the Sentinel System to include 700 million patient records. The region benefits from the Emerging Drug Safety Technology Program, which allows sponsors to pre-clear innovative AI models. This approach reduces the challenges of retrospective validation and accelerates platform adoption. U.S. sponsors are increasingly implementing real-world evidence pipelines that integrate EHR data, claims, and patient-generated health data. This integration increases both the volume and complexity of safety signals, requiring AI-driven triage.

Asia-Pacific is projected to achieve the fastest global CAGR of 18.54% through 2031. China's updated Pharmacovigilance Inspection Guidelines and mandatory data sovereignty regulations resulted in a 40% increase in on-premises platform agreements in 2025. Japan's expansion of the MID-NET database to cover 23 million patients enables device manufacturers to conduct post-market follow-ups without the need for new patient recruitment. This development reduces evidence-generation timelines from 18 months to just 6 months. Similarly, Australia and South Korea are establishing interconnected claims-EHR networks, creating significant opportunities for vendors to incorporate country-specific localization features.

Europe secured approximately one-third of the 2025 revenue, driven by the 2022 E2B(R3) mandate that prompted rapid modernizations. Under the Medical Device Regulation, device manufacturers face stringent post-market clinical follow-up requirements, which in turn expand the market size for AI in post-market surveillance across Europe. However, fragmented national device registries and varying health-data governance standards continue to hinder data consolidation, fostering the adoption of federated-analytics solutions. While the Middle East & Africa and South America collectively represent less than 10% of the revenue, they are expected to grow as cloud-native platforms overcome local IT infrastructure limitations.

List of Companies Covered in this Report:

• AB Cube
• Accenture
• Aris Global
• AssurX
• Cognizant
• Ennov
• Ennov
• ETQ, LLC.
• EVERSANA
• EXTEDO
• Generis Knowledge Management, Inc.
• Greenlight Guru
• Honeywell International
• IQVIA
• MasterControl Inc.
• Oracle
• SAS Institute
• Tata Consultancy Services Limited.
• Veeva Systems
• Wipro

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support